SMARCA1 and neoplasm: So targeted studies on the mutation of SWI/SNF complex subunits in these cancers can undoubtedly increase our knowledge of tumour development, provide effective evidence for the design of targeted molecular drugs, and even lay a solid foundation for the adjuvant diagnosis and treatment of clinical tumours, with the ultimate goal of enhancing the possibility of tumour prevention and cure.